- Home
- NEGG vs CRDF Comparison
NEGG vs CRDF Comparison
Compare NEGG & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEGG
- CRDF
- Stock Information
- Founded
- NEGG 2001
- CRDF 1999
- Country
- NEGG United States
- CRDF United States
- Employees
- NEGG N/A
- CRDF N/A
- Industry
- NEGG Other Specialty Stores
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NEGG Consumer Discretionary
- CRDF Health Care
- Exchange
- NEGG Nasdaq
- CRDF Nasdaq
- Market Cap
- NEGG 122.3M
- CRDF 144.4M
- IPO Year
- NEGG 2010
- CRDF N/A
- Fundamental
- Price
- NEGG $42.55
- CRDF $2.00
- Analyst Decision
- NEGG
- CRDF Strong Buy
- Analyst Count
- NEGG 0
- CRDF 5
- Target Price
- NEGG N/A
- CRDF $11.10
- AVG Volume (30 Days)
- NEGG 2.2M
- CRDF 1.1M
- Earning Date
- NEGG 08-29-2025
- CRDF 11-06-2025
- Dividend Yield
- NEGG N/A
- CRDF N/A
- EPS Growth
- NEGG N/A
- CRDF N/A
- EPS
- NEGG N/A
- CRDF N/A
- Revenue
- NEGG $1,313,127,000.00
- CRDF $545,000.00
- Revenue This Year
- NEGG N/A
- CRDF N/A
- Revenue Next Year
- NEGG N/A
- CRDF N/A
- P/E Ratio
- NEGG N/A
- CRDF N/A
- Revenue Growth
- NEGG N/A
- CRDF N/A
- 52 Week Low
- NEGG $3.32
- CRDF $1.90
- 52 Week High
- NEGG $137.84
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- NEGG 44.50
- CRDF 34.76
- Support Level
- NEGG $33.52
- CRDF $1.97
- Resistance Level
- NEGG $48.15
- CRDF $2.27
- Average True Range (ATR)
- NEGG 8.30
- CRDF 0.12
- MACD
- NEGG -1.95
- CRDF 0.03
- Stochastic Oscillator
- NEGG 30.02
- CRDF 27.03
About NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally. Geographically, it operates in United States, Canada, and Rest of World.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.